- Home
- TKLF vs TOVX Comparison
TKLF vs TOVX Comparison
Compare TKLF & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TKLF | TOVX |
|---|---|---|
| Founded | 2006 | 2001 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 10.1M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | TKLF | TOVX |
|---|---|---|
| Price | $1.75 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 13.9K | ★ 465.0K |
| Earning Date | 12-19-2025 | 05-13-2026 |
| Dividend Yield | ★ 10.97% | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.69 | $0.16 |
| 52 Week High | $4.32 | $0.86 |
Technical Indicators
Market Signals| Indicator | TKLF | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 38.12 | 53.04 |
| Support Level | $1.78 | $0.22 |
| Resistance Level | $2.39 | $0.26 |
| Average True Range (ATR) | 0.09 | 0.01 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 25.01 | 48.10 |
Price Performance
Historical ComparisonAbout TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.